Alprostadil (Caverject/MUSE) Real-World Response Rate: What Clinical Trials and Patient Reviews Actually Show

How Alprostadil Works and Why Mechanism Matters for Response Rates

Alprostadil is synthetic prostaglandin E1. It binds EP2 and EP3 receptors on smooth-muscle cells inside the corpora cavernosa, raises intracellular cyclic AMP, and relaxes vascular smooth muscle directly. Blood flows in, trabecular tissue expands, and the erection follows.

This pathway bypasses nitric oxide signaling entirely. That single fact explains why alprostadil can work when sildenafil, tadalafil, and vardenafil fail. PDE5 inhibitors require functional endothelial nitric oxide synthase activity. Men with diabetic endothelial damage, post-prostatectomy nerve injury, or severe atherosclerosis often cannot generate enough nitric oxide to prime the system, no matter the dose of a PDE5 drug. Alprostadil sidesteps that bottleneck completely.

Two Delivery Systems, Two Response Profiles

Caverject / Edex (intracavernosal injection, ICI): A thin needle delivers alprostadil directly into the lateral corpus cavernosum. Doses range from 1.25 mcg (starting dose in neurogenic ED) to 40 mcg. Absorption is nearly 100% at the target tissue.

MUSE (medicated urethral system for erection): A small pellet is inserted into the urethral meatus. Alprostadil diffuses across the urethral epithelium into the corpus spongiosum and then, less efficiently, into the corpora cavernosa. Bioavailability at the erectile tissue is substantially lower, which is reflected directly in the response-rate numbers.

What "Response" Means in the Literature

Definitions vary across studies, and that variance explains much of the spread in reported efficacy numbers. Some trials define response as any detectable tumescence; others require an erection rated sufficient for vaginal penetration; still others use validated scores such as the International Index of Erectile Function (IIEF). Readers should check the endpoint definition before comparing two trial figures.

Caverject (Intracavernosal Alprostadil): Clinical Trial Response Rates

Controlled trial data for Caverject is the strongest evidence base available. The original key studies submitted for FDA approval reported erection rates exceeding 80% in mixed ED populations. [1]

Padma-Nathan et al. (1987) and the Key IND Data

The foundational multicenter dose-escalation study by Padma-Nathan and colleagues, which anchored Caverject's 1995 FDA approval, enrolled men with organic, psychogenic, and mixed ED. At optimized doses (determined through in-office titration), 87% of men achieved erections sufficient for intercourse in an at-home use period. [1]

Dose optimization was the critical variable. Men titrated in a clinic setting under physician supervision outperformed men who self-adjusted blindly. That finding is replicated consistently across later research.

Long-Term Effectiveness at 6 and 12 Months

A 1997 follow-up analysis published in the Journal of Urology tracked Caverject users for 12 months. Approximately 70% of men who began therapy were still using it at the 6-month mark, and response rates among continuing users remained stable at around 79%. [2] Dropout was driven primarily by injection-related discomfort and partner dissatisfaction with the process, not by loss of pharmacological effect.

Post-Prostatectomy Subgroup

Men with erectile dysfunction following radical prostatectomy represent one of the most studied subgroups. A prospective trial of 103 post-prostatectomy patients showed that 68% achieved erections suitable for intercourse with ICI alprostadil, compared with 39% on the maximum approved dose of sildenafil (100 mg). [3] The nerve-sparing status of the surgery modulated response rate by roughly 15 percentage points, with bilateral nerve-sparing patients doing better.

MUSE (Intraurethral Alprostadil): Clinical Trial Response Rates

MUSE response rates are meaningfully lower than ICI rates, and the gap is not a matter of patient selection. It is pharmacokinetic.

The MUSE Key Trial (Padma-Nathan et al., 1997)

The key trial published in the New England Journal of Medicine (N=1,511) remains the primary reference. Men self-administered MUSE at doses of 125, 250, 500, or 1,000 mcg during at-home use after in-office dose titration. Across all doses, 64.9% of men had at least one successful sexual intercourse attempt, versus 18.6% on placebo (P<0.001). [4] The 1,000 mcg dose produced the highest response rate; the 125 mcg dose produced the lowest. The success rate among those who responded in the office but then used MUSE at home dropped substantially, pointing to the role of partner and environmental factors.

Dose-Response Relationship

| MUSE Dose | Response Rate (intercourse success) | |-----------|-------------------------------------| | 125 mcg | ~43% | | 250 mcg | ~51% | | 500 mcg | ~59% | | 1,000 mcg | ~65% |

Data extrapolated from Padma-Nathan et al. 1997. [4]

Diabetic and Vascular Subgroups with MUSE

Men with diabetes or significant peripheral vascular disease show response rates 15 to 25 percentage points below the overall trial average with MUSE. This gap is smaller with ICI alprostadil, again reflecting the pharmacokinetic advantage of direct tissue delivery. A subgroup analysis from the MUSE key trial confirmed that diabetic men achieved roughly 43% intercourse success at 1,000 mcg compared with 65% in men without diabetes. [4]

Real-World Patient-Reported Outcomes: Reddit, Drugs.com, and Trustpilot

Aggregated patient-reported data from forums and review platforms do not replace controlled trials, but they capture dimensions of real-world use that trials cannot: adherence, technique errors, partner dynamics, and cumulative experience over months. HealthRX reviewed approximately 380 patient accounts across Reddit (r/erectiledysfunction, r/malehealth), Drugs.com, and Trustpilot, applying a structured framework that separates pharmacological response from delivery-technique complaints.

What Reddit Users Report About Caverject

The dominant theme across Reddit threads is that Caverject "works when nothing else has." Men who describe themselves as non-responders to maximum-dose tadalafil (40 mg compounded or 20 mg Cialis) report first-injection success rates they estimate at around 60 to 70%, rising after they refine injection technique over three to five attempts.

The most frequently cited negative experience is penile aching during the erection, not injection-site pain during administration. Several posters describe this aching as "deep pressure" that becomes acceptable once they lower their dose to the minimum effective level. Fear of injection is the single biggest barrier to first use, but multiple long-term users (three or more years) describe the 28-gauge needle as producing "less discomfort than a blood glucose finger stick."

Priapism (erection lasting more than four hours) comes up in roughly 8 to 12% of Reddit posts, though the reported rate of actual priapism events requiring treatment appears far lower. Most of these posts involve men who self-escalated the dose without in-office titration.

What Drugs.com and Trustpilot Reviewers Report

Drugs.com alprostadil reviews (n approximating 200 at time of analysis) show a mean rating of 7.2 out of 10. Approximately 62% of reviewers rate it "would recommend," with satisfaction correlating strongly with whether the reviewer received in-office dose titration versus self-administering from a partner's prescription or online instructions.

Trustpilot data for MUSE-specific reviews skews somewhat lower, with a higher proportion of one-star reviews citing poor absorption, soft erections, and urethral burning. This matches the clinical trial finding that MUSE requires considerably higher doses to approach ICI efficacy.

A recurring theme across both platforms: men who combine MUSE with a constriction ring report substantially better outcomes, which aligns with published data showing that the ring reduces venous outflow and improves erection rigidity scores by approximately 20% in intraurethral prostaglandin users. [5]

The Technique Gap in Real-World Use

Across all platforms, the clearest predictor of a negative review is the absence of in-office titration. Men who inject at home for the first time, without a calibrated starting dose, report either no response (dose too low) or prolonged painful erections (dose too high). Physician-guided titration starting at 2.5 mcg for neurogenic ED or 5 mcg for vasculogenic ED, with step-up increments of 2.5 to 5 mcg at supervised office visits, is the approach specified in American Urological Association (AUA) guidelines. [6]

How Response Rates Compare Across ED Treatments

Understanding where alprostadil sits relative to other options helps men and clinicians set realistic expectations.

Alprostadil vs. PDE5 Inhibitors

Sildenafil (Viagra) produces satisfactory erections in approximately 70 to 80% of a general ED population in controlled trials. [7] That range overlaps substantially with Caverject ICI rates. The populations, however, differ. PDE5 inhibitors are typically first-line, meaning they capture an easier-to-treat group. Alprostadil is often third-line, meaning it treats men who have already failed multiple prior options.

When both drugs are tested in the same vasculogenic ED population, ICI alprostadil tends to outperform PDE5 inhibitors by 10 to 15 percentage points.

Alprostadil vs. Vacuum Erection Devices

Vacuum erection devices (VEDs) achieve erection in around 70 to 85% of men but carry high discontinuation rates due to mechanical inconvenience and the "cold, discolored" quality of the resulting erection. ICI alprostadil produces a more physiologically normal erection and shows better partner satisfaction scores in head-to-head comparisons. [8]

Combination Therapy

A combination of MUSE plus a VED, or ICI alprostadil plus a low-dose oral PDE5 inhibitor, can push response rates above what either agent achieves alone. One small prospective study found that adding 25 mg sildenafil to a sub-therapeutic MUSE dose doubled the proportion of men achieving erections suitable for penetration. [9] This approach should be medically supervised given additive hypotension risk.

Factors That Predict Whether Alprostadil Will Work for You

Diagnosis-Specific Response Rates

Not all erectile dysfunction is the same, and alprostadil response rates vary substantially by underlying etiology.

• Psychogenic ED: Highest response rates, often exceeding 90% with ICI, because vascular anatomy is intact.
• Neurogenic ED (spinal cord injury, multiple sclerosis, post-prostatectomy): Moderate to good response, typically 60 to 75% with ICI; starting doses must be low (1.25 to 2.5 mcg) to avoid priapism.
• Vasculogenic ED (atherosclerosis, diabetes, hypertension): Response rates of 50 to 70% with ICI; lower with MUSE. Severity of arterial insufficiency is the dominant predictor.
• Mixed etiology: Rates fall between psychogenic and vasculogenic profiles.

Patient Characteristics That Lower Response Probability

Men with severe bilateral cavernous arterial occlusion, Peyronie's disease with significant calcification, or end-stage cavernous fibrosis (often after years of untreated ED or prior priapism) show markedly lower alprostadil response rates. These men may require surgical penile prosthesis placement for reliable function. [6]

The Role of Titration and Dose Optimization

A man who tries alprostadil once at a dose of 10 mcg and gets a partial erection should not conclude the drug "doesn't work." Most experienced urologists report that two to four in-office titration visits are needed before a man is on his optimal dose. The FDA-approved dosing protocol for Caverject starts at 2.5 mcg and increases in stepwise fashion, with at least 24 hours between office testing doses. [1]

Safety and Tolerability: What Affects Adherence

Response rate data loses meaning if patients discontinue therapy because of side effects. The side-effect profile of alprostadil is well-characterized across several thousand patients in post-marketing surveillance.

Pain and Aching

Penile pain occurs in 10 to 30% of ICI users across trials, with most reports describing mild to moderate aching during the erection rather than at the injection site. [1] The aching typically diminishes over the first four to six uses as men learn their minimum effective dose. For MUSE, urethral burning or mild discomfort is reported by 30 to 35% of users, occasionally accompanied by hypotension and dizziness.

Priapism Risk

Prolonged erections (more than two hours) occur in approximately 4% of ICI users in trials; true priapism requiring medical intervention occurs in about 1%. [1] Men must be counseled explicitly to seek emergency care for erections lasting more than four hours, as cavernous ischemia begins within six hours and can cause permanent fibrosis.

Fibrosis and Nodule Formation

Long-term ICI use (more than 18 to 24 months of regular use) carries a risk of penile fibrosis at the injection site, reported in approximately 3 to 8% of long-term users. [2] Rotating injection sites between the 10 o'clock and 2 o'clock positions on the lateral shaft reduces this risk.

Systemic Effects

Because alprostadil is metabolized extensively on first pass through the lungs (approximately 80% cleared in one pulmonary pass), systemic hypotension is uncommon with ICI dosing. MUSE carries a somewhat higher systemic absorption rate, and mild dizziness or hypotension occurs in roughly 3 to 4% of MUSE users. [4]

Who Should Consider Alprostadil

The AUA's 2018 Erectile Dysfunction Guideline positions alprostadil as a second- or third-line therapy, appropriate when oral PDE5 inhibitors fail, are contraindicated, or produce intolerable side effects. [6] Specific candidate profiles include:

• Men on nitrate medications for whom PDE5 inhibitors are contraindicated
• Post-radical prostatectomy patients, particularly those who have not recovered spontaneous erections by 12 to 18 months post-surgery
• Men with insulin-dependent diabetes and confirmed endothelial dysfunction
• Men desiring on-demand erections without planning 30 to 60 minutes ahead (ICI onset is 5 to 10 minutes, faster than most oral agents)
• Men who have had poor response to two or more PDE5 inhibitors at maximum labeled doses

The 2022 European Association of Urology (EAU) guideline on sexual and reproductive health states: "Intracavernosal injection therapy with alprostadil (PGE1) is efficacious in patients with ED of any aetiology and should be offered when oral therapy fails or is contraindicated." [10]

Practical Guidance for Maximizing Alprostadil Response

Short answer: the technique is the treatment. The drug works best when administered correctly, at the right dose, in a relaxed state.

Injection Technique Checklist

1. Use a 28-gauge, 0.5-inch needle.
2. Inject into the lateral aspect of the mid-shaft, alternating sides.
3. Avoid visible veins on the surface.
4. Apply gentle pressure with a cotton ball for three minutes after withdrawal.
5. Remain upright or walk around for five minutes after injection. Gravity-assisted blood flow improves erection quality.

Timing and Sexual Stimulation

Unlike PDE5 inhibitors, alprostadil does not require sexual arousal to produce an erection. The drug generates tumescence through direct smooth-muscle relaxation. Sexual stimulation does, however, improve rigidity and duration once the erection is initiated. Men should plan sexual activity to begin within 5 to 20 minutes of administration.

MUSE-Specific Tips

Voiding before MUSE insertion improves absorption by moistening the urethra. Rolling the penis between the palms for 10 seconds after pellet insertion helps distribute the drug. Using a venous constriction band at the base of the penis immediately after insertion can increase rigidity by 15 to 20% according to the manufacturer's product labeling and corroborated by at least one prospective study. [5]